Novo Nordisk launched Ozempic in India on Friday, pricing the 0.25 mg dose at $24.35 per week as it targets a fast-growing ...

Danish drugmaker Novo Nordisk launched its blockbuster diabetes drug Ozempic in India on Friday, pricing the lowest dose of 0 ...

A proposed new federal law could provide some competitive guardrails for the company's most important product.

In an interview, Novo Nordisk India’s managing director Vikrant Shrotriya discusses the launch of Ozempic, the company’s ...

Healthcare giant Novo Nordisk A/S (NYSE:NVO)’s shares were downgraded by Argus Research to Hold from Buy on December 8th, The ...

The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has recommended granting approval to Novo Nordisk India for its proposed update to ...

Dec 12 () - Danish drugmaker ​Novo Nordisk ‌launched its blockbuster diabetes drug ‌Ozempic in India on Friday. Ozempic, a ...

The launch comes amid the company’s legal battle with Indian drugmakers, including Dr Reddy’s Laboratories and Sun Pharma, ...

Novo Nordisk (NYSE: NVO) stock was slimming down on Monday, but not in the way any investor in the Wegovy and Ozempic ...

The European Medicines Agency (EMA) has issued a positive opinion for a new Wegovy® 7.2 mg dose, advancing its availability ...

The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.

Danish drugmaker Novo Nordisk will launch its blockbuster diabetes drug Ozempic in India this month, three sources familiar ...